Investigators → Rebecca M. Okafor
ORA-W-SEA · Pacific Northwest Division (Seattle District)
Strictness Percentile: 59th
Rebecca M. Okafor — FDA Investigator Citation Profile
Focuses heavily on 21 CFR 117.10 and 21 CFR 1.502(a). Expect a request for your Approved Supplier List, raw component identity testing chromatograms, and last 24 months of OOS/CAPA logs within the first 2 hours of opening conference.
Top Cited Clauses: 21 CFR 117.10, 21 CFR 1.502(a), 21 CFR 820.50
Simulate Inspection by Rebecca M. Okafor →
Recent Form 483s Linked to Rebecca M. Okafor
Houston Rx LLC (2026-08-28) · 4 observations
View 483 →Cascade Specialty Pharmacy LLC (2026-07-17) · 4 observations
View 483 →Sincerus Florida, LLC (2026-05-29) · 4 observations
View 483 →VA San Diego Healthcare Systems (2026-05-08) · 4 observations
View 483 →Catalent Indiana LLC (2026-04-24) · 4 observations
View 483 →Central Alabama Veterans Health Care System (2026-04-16) · 4 observations
View 483 →Bentley Laboratories LLC (2026-03-27) · 4 observations
View 483 →Dendreon Pharmaceuticals LLC (2026-03-25) · 4 observations
View 483 →Eosera, Inc. (2026-03-20) · 4 observations
View 483 →BioChem Sioux City, Inc. (2026-03-19) · 4 observations
View 483 →Isorx Cyclotron Center (2026-03-13) · 4 observations
View 483 →VET4U, LLC (2026-03-11) · 4 observations
View 483 →IsoTis OrthoBiologics, Inc. (2026-03-06) · 4 observations
View 483 →Fresh & Ready Foods LLC (2026-03-04) · 4 observations
View 483 →Brio Pharmaceuticals Inc (2026-02-27) · 4 observations
View 483 →